Advanced Clinical Research & Publications
Prof. Dr. Serdar Baki Albayrak specializes in advanced microneurosurgical resections of high-grade gliomas and pioneering autologous immunotherapy clinical studies. This resource center compiles our peer-reviewed publications, case studies on compassionate use immunotherapy, and comprehensive guides designed to support patients and clinical researchers with scientifically backed data on brain tumor management.
Tumor Immunized Autologous Natural Killer Cell (NK) Therapy / Compassionate Use
A peer-reviewed clinical letter detailing the successful cultivation and administration of autologous tumor-immunized NK cell immunotherapy for a patient with pontine glioma (DIPG/Grade 4 Astrocytoma), illustrating the workflow from surgical resection to laboratory immunization.
Malignant Gliomas: Comprehensive Patient Guide & Advanced Immunotherapeutic Approaches
An in-depth, patient-friendly, and scientifically detailed guidebook explaining the molecular biology, advanced diagnostic techniques, modern neurosurgical resection principles, and groundbreaking autologous NK cell immunotherapies.
Frequently Asked Questions
What is Autologous Natural Killer (NK) Cell Immunotherapy?
Autologous NK Cell Immunotherapy is an advanced cellular cancer treatment that uses the patient’s own Natural Killer cells. These cells are innate immune lymphocytes capable of identifying and destroying cancer cells without prior sensitization. In clinical practice, tumor cells harvested during neurosurgery are used in vitro to immunize and activate the patient’s NK cells, which are then re-infused intravenously to target the tumor.
Is this treatment safe for patients with high-grade gliomas?
According to the clinical study published by Prof. Dr. Serdar Baki Albayrak and colleagues, the intravenous administration of autologous tumor-immunized NK cells demonstrated excellent safety profiles under compassionate-use guidelines. The trials showed no early or late adverse reactions, such as infections, anaphylaxis, or thrombosis.
What role does surgery play in personalized immunotherapy?
Surgery is the first and most critical step. In addition to maximal safe tumor resection and tumor debulking, surgery provides the essential live tumor tissue needed for personalized therapy. This harvested tumor tissue is sent to cell culture laboratories to cultivate the specific antigens used to immunize and activate the patient’s own NK cells.
Can NK Cell Therapy be used for pontine glioma (DIPG)?
Yes. The published case report demonstrates the feasibility of autologous tumor-immunized NK cell therapy as a compassionate-use treatment for Diffuse Infiltrative Pontine Glioma (DIPG/Grade 4 Astrocytoma). Post-treatment scans showed stabilization and tumor necrosis without increasing pons edema.